168 related articles for article (PubMed ID: 16393726)
1. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma.
Pinnas JL; Noonan MJ; Weinstein SF; Chervinsky P; Scott CA; Herje NE; Wu W; Crim C
J Asthma; 2005 Dec; 42(10):865-71. PubMed ID: 16393726
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
3. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
Lumry WR; Conway MM; LaForce CF; Pearlman DS; Scott CA; Herje NE; Wu WW; Crim C
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
[TBL] [Abstract][Full Text] [Related]
5. Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.
Edin HM; Andersen LB; Schoaf L; Scott-Wilson CA; Ho SY; Ortega HG
Ann Allergy Asthma Immunol; 2009 Apr; 102(4):323-7. PubMed ID: 19441604
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG; Millar AB; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
Perruchoud AP; Lundback B; Yigla M; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
You-Ning L; Humphries M; Du X; Wang L; Jiang J
Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment.
Nelson HS; Wolfe JD; Gross G; Greos LS; Baitinger L; Scott C; Dorinsky P
Ann Allergy Asthma Immunol; 2003 Sep; 91(3):263-9. PubMed ID: 14533658
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
Wasserman RL; Baker JW; Kim KT; Blake KV; Scott CA; Wu W; Faris MA; Crim C
Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.
Qaqundah PY; Sugerman RW; Ceruti E; Maspero JF; Kleha JF; Scott CA; Wu W; Mehta R; Crim C
J Pediatr; 2006 Nov; 149(5):663-670. PubMed ID: 17095339
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma.
Pearlman DS; Noonan MJ; Tashkin DP; Goldstein MF; Hamedani AG; Kellerman DJ; Schaberg A
Ann Allergy Asthma Immunol; 1997 Apr; 78(4):356-62. PubMed ID: 9109702
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma.
Pearlman DS; Peden D; Condemi JJ; Weinstein S; White M; Baitinger L; Scott C; Ho SY; House K; Dorinsky P
J Asthma; 2004; 41(8):797-806. PubMed ID: 15641629
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
Medley H; Orozco S; Allen A
Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
[TBL] [Abstract][Full Text] [Related]
17. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children.
Lyttle B; Gilles J; Panov M; Emeryk A; Wixon C
Can Respir J; 2003 Mar; 10(2):103-9. PubMed ID: 12687029
[TBL] [Abstract][Full Text] [Related]
18. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218
[TBL] [Abstract][Full Text] [Related]
19. Efficacy response of inhaled HFA-albuterol delivered via the breath-actuated Autohaler inhalation device is comparable to dose in patients with asthma.
Gross G; Cohen RM; Guy H
J Asthma; 2003; 40(5):487-95. PubMed ID: 14529098
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
